News und Analysen

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have risen more than 2,000% over the past 20 years. Despite a terrific run-up, it's hard to find an investment bank analyst on Wall Street who expects

Between labor-market data and potential interest-rate cuts, Wall Street has a lot on its plate right now. In an environment like this one, it can be helpful to invest in solid, dividend-paying

A streak lasting decades is noteworthy. Whether it's a silver wedding anniversary, a quarter century of work, or The Simpsons' 37-year run, these show stability and success.

You can find examples in

Some decisions are tough to make. Others are so easy that they don't require much thought and are practically no-brainers.

Three Motley Fool contributors believe they've identified dividend stocks

If you're a long-term investor, why should you be paying closer attention to pharmaceutical giant Pfizer (NYSE: PFE)? Because of its dividend, of course! Pfizer's dividend yield is hovering around a

A star stock during the pandemic era wasn't shining so brightly on Friday. On a media report that the current presidential administration is preparing to link a set of fatalities to Covid vaccines

AbbVie (NYSE: ABBV) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the

enGene (NASDAQ:ENGN), a clinical-stage gene therapy company advancing treatments for bladder cancer, released its fiscal 2025 third-quarter earnings on Sept. 11, 2025. The period was highlighted by

KalVista Pharmaceuticals (NASDAQ:KALV), a biopharmaceutical company developing and commercializing therapies for rare diseases, announced its earnings for the first quarter of fiscal 2026 on Sept

It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard

Shares of Earth-imaging satellites company BlackSky Technology (NYSE: BKSY) soared 13.5% through 3 p.m. ET Thursday -- probably because of a couple of tweets posted on X announcing BlackSky's plans

Shares of AbbVie (NYSE: ABBV) were jumping 4.2% higher as of 11:37 a.m. ET on Thursday. The nice gain came after the big drugmaker revealed that it had settled litigation with all companies that

In 2023, Nvidia's (NASDAQ: NVDA) H100 graphics processing unit (GPU) for the data center was the world's most popular artificial intelligence (AI) chip, granting the company a staggering 98% market

Advanced Micro Devices (NASDAQ: AMD) stock is climbing today thanks to strong results from another player in the artificial intelligence (AI) space. The company's share price was up 1.8% as of 3

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the special offer link below.

The artificial intelligence (AI) data center chip market is projected to reach $286 billion by 2030, up from $123 billion in 2024. Yet while investors chase Nvidia (NASDAQ: NVDA) to astronomical

In this video, I will cover the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.

When the market opened on

Quick -- what were you doing back in September of 2022? Were you buying $10,000 of stock in Amgen (NASDAQ: AMGN)? If so, you might be wondering what that's worth today. Even if you didn't buy Amgen

With patent-protected market exclusivity for their products, pharmaceutical companies reliably produce profits that they aren't shy about distributing to shareholders. In an industry already known

The market was less than impressed with the top-line results from Viking Therapeutics' (NASDAQ: VKTX) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created

Pfizer (NYSE: PFE) is a fairly well-known drugmaker, with a name that even non-healthcare-oriented types would likely know. That's a testament to the company's longevity and its success as a

Investors haven't been kind to Intuitive Surgical (NASDAQ: ISRG) and Regeneron Pharmaceuticals (NASDAQ: REGN) this year. Both healthcare leaders have encountered company-specific issues that have

What's one of the biggest mistakes investors make? Selling stocks too soon. It's smarter to try to adhere to Warren Buffett's favorite holding period of "forever," or at least as close to that goal

BioNTech (NASDAQ: BNTX), the Germany-based biotech that scored big early in the pandemic era with the Comirnaty vaccine it developed with Pfizer, had some fresh news from the lab to report on